Nuclear receptors in early hormone refractory prostate cancer and their relationship to apoptosis-related proteins

Neoplasma

Volumn 49, Issue 3, 2002, Pages 172-177

  Kolar Z ^a   Murray, P G ^a   Madarova J ^a   Lukesova M ^a   Hlobilkova A ^a   Rihakova P ^a   Flavell, J R ^a   Strnad, M ^a   Student V ^a   Vojtesek B ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Androgen ablation; Bcl 2 family; Cell cycle; Nuclear receptors; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; ANTIANDROGEN; CELL NUCLEUS RECEPTOR; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P27; RETINOID X RECEPTOR;

APOPTOSIS; ARTICLE; CANCER STAGING; CELL CYCLE; CELL TYPE; CONTROLLED STUDY; HORMONAL REGULATION; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; MULTIGENE FAMILY; PROSTATE CANCER; PROTEIN EXPRESSION; RECEPTOR SENSITIVITY; SIGNAL TRANSDUCTION;

EID: 0036299794     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer
2. Prognostic markers in clinically localised prostate cancer
3. Molecular correlates of bcl-2-enhanced growth following androgen-ablation in prostate carcinoma cells in vivo
4. Androgens induce resistance to bcl-2-mediated apoptosis in LNCaP prostate cancer cells
5. Bcl-x, a bcl-2-regulated gene that functions as a dominant regulator of apoptotic cell death
6. Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy
7. Prognostic significance of Bcl-2 in clinically localized prostate cancer
8. Predictive value of bcl-2 immunoreactivity in prostate cancer patients treated with radiotherapy
9. Growth of LNCaP human prostate cancer cells is stimulated by estradiol via its own receptor
10. Expression of p27kip1 in prostatic adenokarcinoma
11. Nuclear localization of androgen receptor in heterogeneous samples of normal, hyperplastic and neoplastic human prostate
12. Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio
13. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormonerefractory human prostate cancer
14. Prostate stem cell compartments. Expression of the cell cycle inhibitor p27Kip1 in normal, hyperplastic, and neoplastic cells
15. Basic science aspects of prostate cancer
16. Prediction of progression following radical prostatectomy
17. Expression of p27/kip1 is down-regulated in human prostate carcinoma progression
18. Immunocytochemical localization of Bcl-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy
19. A superfamily of potentially oncogenic hormone receptors
20. Loss of the cyclin-dependent kinase inhibitor p27(Kip1) protein in human prostate cancer correlates with tumor grade
21. Androgen receptors in cancer of the prostate. Correlation with the stage and grade of the tumor
22. Metastatic lesions from prostate cancer do not express oestrogen and progesterone receptors
23. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death
24. Effects of 1,25 dihydroxyvitamin D3 and its analogues on induction of apoptosis in breast cancer cells
25. The prognostic significance of p34cdc2 and cyklin D1 protein expression in prostate adenocarcinoma
26. Androgen receptor alterations in prostatic carcinoma
27. Androgen receptor gene amplification: A possible molecular mechanism for androgen deprivation. Therapy failure in prostate cancer
28. Increased cell proliferation activity and decreased cell death are associated with the emergence of hormone-refractory recurrent prostate cancer
29. Bax degradation by the ubiquitin/proteasome-dependent pathway:Involvement in tumor survival and progression
30. Expression of the proto-oncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer
31. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death
32. An elevated bax/bcl-2 ratio corresponds with the onset of prostate epithelial cell apoptosis
33. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo
34. Bcl-2: Prevention of apoptosis as a mechanism of drug resistance
35. The androgen receptor in prostate cancer
36. From estrogen to androgen receptor: A new pathway for sex hormones in prostate